DNLI Denali Therapeutics

Watchlist

13.810
-0.310-2.20%

Close Mar 26 16:00 ET

13.880
+0.070+0.51%

Pre 07:00 ET

2.01BMarket Cap-5.37P/E (TTM)

About Denali Therapeutics Company

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Company Profile

SymbolDNLI

Company NameDenali Therapeutics

Listing DateDec 8, 2017

Issue Price18.00

Founded2013

CEODr. Ryan J. Watts, PhD

MarketNASDAQ

Employees422

Fiscal Year Ends12-31

Address161 Oyster Point Boulevard

CitySan Francisco

ProvinceCalifornia

CountryUnited States of America

Zip Code94080

Phone1-615-866-8548

Websitehttp://www.denalitherapeutics.com

Company Executives

Name
Position
Salary

Dr. Ryan J. Watts, PhD
Director, President and Chief Executive Officer
7.88M

Dr. Carole Ho, M.D.
Chief Medical Officer and Head of Development
4.17M

Dr. Alexander O. Schuth, M.D.
Secretary, Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer
4.17M

Dr. Vicki L. Sato, PhD
Chairman of the Board
459.43K

Steven E. Krognes
Director
419.43K

Nancy A. Thornberry
Independent Director
434.43K

Jennifer E. Cook
Independent Director
429.43K

Peter S. Klein
Independent Director
439.43K

Jay T. Flatley
Independent Director
444.43K

Erik Harris
Independent Director
429.43K

Dr. Marc Tessier-Lavigne, PhD
Independent Director
431.93K

Dr. David P. Schenkein, M.D.
Independent Director
439.43K

DNLI Denali Therapeutics

About Denali Therapeutics Company

Company Profile

Company Executives

Market Insights